Press releases
- Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
- Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
- Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
- Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
- Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency¹) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)
- Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
- Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor
- Imperative Care Announces Four Senior Leadership Appointments
More ▼
Key statistics
On Thursday, Insulet Corp (P2OD34:SAO) closed at 27.91, 0.00% above its 52-week low of 27.91, set on Mar 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 27.91 |
---|---|
High | 27.91 |
Low | 27.91 |
Bid | 28.11 |
Offer | 35.00 |
Previous close | 27.91 |
Average volume | -- |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Apr 25 2024 20:54 BST.
More ▼